Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Shares Issued (2022 - 2025)

Prime Medicine's Shares Issued history spans 4 years, with the latest figure at $408000.0 for Q4 2025.

  • For Q4 2025, Shares Issued fell 97.88% year-over-year to $408000.0; the TTM value through Dec 2025 reached $781000.0, down 97.95%, while the annual FY2025 figure was $781000.0, 97.95% down from the prior year.
  • Shares Issued reached $408000.0 in Q4 2025 per PRME's latest filing, up from $373000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $19.3 million in Q4 2024 to a low of -$1.1 million in Q2 2024.
  • Average Shares Issued over 4 years is $3.3 million, with a median of $264500.0 recorded in 2022.
  • The largest YoY upside for Shares Issued was 13197.2% in 2024 against a maximum downside of 1605.33% in 2024.
  • A 4-year view of Shares Issued shows it stood at $156000.0 in 2022, then soared by 319.87% to $655000.0 in 2023, then skyrocketed by 2843.66% to $19.3 million in 2024, then crashed by 97.88% to $408000.0 in 2025.
  • Per Business Quant, the three most recent readings for PRME's Shares Issued are $408000.0 (Q4 2025), $373000.0 (Q3 2025), and $19.3 million (Q4 2024).